智飞生物：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗临床试验申请获得受理

Core Viewpoint - The company has received a clinical trial application acceptance notice for its modified Ankara vaccinia virus (MVA) monkeypox live attenuated vaccine, marking a significant breakthrough in its vaccine development efforts [1] Group 1: Clinical Trial Development - The clinical trial application for the modified MVA monkeypox vaccine was accepted by the National Medical Products Administration, allowing the company to proceed with trials if no objections are raised within 60 days [1] - The vaccine utilizes a modified Ankara strain that cannot effectively replicate in human cells, ensuring high safety levels and preventing secondary transmission [1] Group 2: Strategic Implications - This acceptance signifies a key breakthrough in the company's focus on innovative technologies and core competencies in addressing emerging infectious diseases [1] - Successful progress in this project is expected to enhance the company's vaccine portfolio, improve product layout, and strengthen its market position [1]